* Emisphere Technologies Inc., of Hawthorne, N.Y., presented data from clinical and preclinical oral heparin studies at the annual meeting of the American Association of Pharmaceutical Scientists, in Boston. In the clinical study, an oral formulation produced clinically relevant levels of heparin and dose-dependent clotting time. In separate pre-clinical primate studies of two orally delivered low-molecular weight versions, the company found that a sodium-N-amino decanoate carrier was four times more efficient than a sodium-N-amino caprylate carrier.
* Genzyme Molecular Oncology, a division of Cambridge, Mass.-based Genzyme Corp., said Warner-Lambert Co., of Morris Plains, N.J., signed an option-agreement for Genzyme Molecular's Serial Analysis of Gene Expression (SAGE) technology. If Warner-Lambert exercises the option for non-exclusive use of the SAGE technology, Genzyme Molecular could receive more than $9 million. Warner-Lambert's Parke-Davis Research Division initially will evaluate SAGE for pharmacogenomics, which involves analyzing gene expression changes in tissues treated with drug candidates.
* Hoffmann-La Roche Inc., of Nutley, N.J., the U.S. subsidiary of Basel, Switzerland-based Roche Holding Ltd., said the FDA approved Fortovase (saquinavir), an improved form of its marketed HIV protease inhibitor, Invirase (saquinavir mesylate). Fortovase, in a gelatin formulation, will be used in adults in combination with other antiretroviral drugs.
* IGG International Inc., of Cambridge, Mass., said its subsidiary, Agricultural Glycosystems Inc., received approval from the Environmental Protection Agency to market IGG's lead agricultural compound, Elexa, in the U.S. Elexa is a naturally derived carbohydrate compound that has been shown to defend a wide variety of crops from fungi. The product shows low toxicity and minimal impact on the environment.
* Pharmacia & Upjohn, of Kalamazoo, Mich., received FDA marketing clearance for Genotropin Lyophilized powder (somatropin of rDNA origin for injection), which provides long-term replacement therapy in adults with growth hormone deficiency. The product was approved for children in August 1995.
* Schering-Plough Corp., of Madison, N.J., said the FDA approved Intron A (interferon alfa-2b) for use with anthracycline-containing combination chemotherapy for treatment of non-Hodgkin's lymphoma. Intron A, licensed from Biogen Inc., of Cambridge, Mass., is recombinant alpha interferon and already is on the market for other forms of cancer and hepatitis.
* Structural Bioinformatics Inc., of San Diego, installed an IBM RS/6000 SP to run computer simulation programs that will speed drug development. The "super computer" can process 16 proteins at a time, calculating surface characteristics and providing the company a ten-fold increase over earlier modeling speeds. The information is used to design biologically useful molecules to affect the proteins.
* Synaptic Pharmaceutical Corp., of Paramus, N.J., said underwriters of the company's $30 million stock offering exercised their overallotment option to purchase an additional 375,000 shares. Proceeds to the company were $4.4 million, bringing to $34.1 million the total raised from the sale of 2.875 million shares. The underwriters are Bear, Stearns & Co., of New York, Hambrecht & Quist LLC, of New York, and Vector Securities International Inc., of Deerfield, Ill.